Quintiles and The Medical Affairs Company Sign Agreement Enhancing Respective Commercial Solutions Capabilities

RESEARCH TRIANGLE PARK, N.C. & KENNESAW, Ga.--()--Quintiles and The Medical Affairs Company (TMAC) today announced a new collaboration that will extend and enhance each company's existing medical affairs-related offerings for customers in the United States.

Under the agreement, Quintiles will add TMAC's industry-leading medical science liaison (MSL) capabilities to its existing field-based medical solutions, providing customers with additional expertise to engage opinion leaders and encourage a heightened knowledge of research, products and devices. The collaboration will also allow TMAC to leverage Quintiles' clinical educators with its clients to facilitate ongoing education of healthcare professionals, patients and caregivers throughout the U.S.

"Today, more than ever before, biopharmaceutical companies looking to commercialize products in the U.S. are focused on demonstrating the value and benefits of their products to an increasingly diverse range of stakeholders," said Daryl Gaugler, senior vice president, Commercial Solutions at Quintiles. "As this stakeholder landscape and its requirements continue to evolve, we are delighted to be working alongside a company like TMAC to offer the full spectrum of commercialization services, with an integrated approach to sales, medical science liaison, clinical education and market entry.

"This collaboration will extend and enhance our ability to deliver integrated commercialization programs for our customers, including for small to medium sized companies, as they consider their options for developing capabilities in the U.S. market."

Working together, Quintiles and TMAC will continue to provide customers with the integrated, multi-disciplinary teams they have come to expect from both companies, but now with an added breadth of expertise. Both companies will utilize the services of the other to bolster existing capabilities and provide comprehensive solutions to their customers in the U.S.

"Requirements for medical affairs activities are expanding across the product life cycle," said Evan Demestihas, M.D., chief executive officer, TMAC. "Working with companies like TMAC and Quintiles provides customers with benefits in terms of strategic oversight, speedy deployment and operational flexibility, while maintaining the discipline-specific and therapy area expertise that are essential to medical affairs teams. Through this collaboration, we believe Quintiles and TMAC will offer customers turn-key field commercialization capabilities that are unmatched in our industry."

About Quintiles

Quintiles (NYSE: Q) is the world's largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

About The Medical Affairs Company

The Medical Affairs Company LLC (TMAC®) is a full service contract medical organization that provides the pharmaceutical, biotechnology, and medical device industries a wide array of outsourcing capabilities for medical affairs activities. Offering both strategic and tactical medical liaison support services in addition to medical liaison consulting and medical communications support, TMAC is uniquely positioned to provide both unmatched value and service to the pharmaceutical industry. TMAC's greatest strength is its focus: medical and scientific affairs - it is their only business. For more information, please visit the Company's website at www.TheMedicalAffairsCompany.com.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.